Cervical Dysplasia - Epidemiology Forecast - 2030

DelveInsight’s "Cervical Dysplasia- Epidemiology Forecast-2032" report delivers an in-depth understanding of the disease, historical and forecasted Cervical Dysplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Cervical Dysplasia Understanding
Cervical dysplasia, also known as cervical intraepithelial neoplasia (CIN), is the abnormal growth of cells on the surface of the cervix or endocervical canal – the opening between the uterus and the vagina. It is usually caused by certain types of human papillomavirus (HPV) and is found when a Pap test or cervical biopsy is done. Depending on how abnormal the cells look under the microscope and how much of the cervical tissue is affected, it can be classified into mild, moderate, or severe. Cervical dysplasia is not cancer but may become cancer and can spread to nearby normal tissue.
The cervix is the lower, narrow end of the uterus that forms a canal between the uterus and vagina. Before cancer cells form in the tissues of the cervix, the cells of the cervix go through abnormal changes called dysplasia. There are different types of dysplasia: mild dysplasia (CIN-1), called low-grade intraepithelial lesion (LSIL); and moderate dysplasia (CIN-2) and severe dysplasia (CIN-3), called high-grade intraepithelial lesion (HSIL). LSIL and HSIL may or may not become cancer. Cervical dysplasia usually causes no symptoms and is most often discovered by a routine Pap test. The prognosis is excellent for women with cervical dysplasia who receive appropriate follow-up and treatment. But women who go undiagnosed or who do not receive appropriate care are at higher risk of developing cervical cancer.
Cervical Dysplasia Diagnosis
All women over the age of 18 who have been sexually active should undergo regular gynecological examinations, including a pelvic exam and Pap test, to detect any abnormal changes to the cervix as soon as possible. Like many other types of cancer, cervical cancer is more likely to be effectively treated if identified early. Inflammation caused by yeast infections, bacterial infections such as trichomonas, gonorrhea, or Chlamydia, other viruses, medicines or other chemicals, hormones, and pregnancy can all be detected with Pap tests.
Cervical cancer screening includes cytology and HPV testing, alone or in combination. Conventional cytology (a Pap test sample affixed to a slide at the time of testing) and liquid-based cytology (a newer method for collecting, transporting, and preparing cells collected by the Pap test in a liquid medium [e.g., ThinPrep Pap test]) provide comparable results. Both methods are acceptable and have nearly equivalent sensitivity and specificity for detecting high-grade CIN.
HPV testing, alone or in combination with cytology, is more sensitive than cytology alone in detecting CIN2 and CIN3. There are a variety of tests approved by the US FDA for detecting cervical HPV, including HPV DNA and HPV mRNA tests. Current methods for using cervical HPV testing in the United States include triage testing for patients with abnormal findings on cytology (reflex testing), adjunct testing with cytology (co-testing), and primary testing.
Epidemiology Perspective by DelveInsight
The Cervical Dysplasia epidemiology division provides insights about historical and current Cervical Dysplasia patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
As per the DelveInsight estimates, in the year 2020, the total diagnosed incident cases of cervical dysplasia were 2,892,687 cases in the 7MM, which are expected to grow during the study period, i.e.,2018-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Cervical Dysplasia epidemiology [segmented as Total Diagnosed Incident Cases of Cervical Dysplasia, Total Diagnosed Incident Cases for Cervical Dysplasia by Severity (without year on year impact of vaccination), Total Age group-specific Cases of Cervical Dysplasia (CIN 2+, with impact of HPV vaccination), and Total Treated Cases of Cervical Dysplasia] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- Cervical Dysplasia Epidemiology
Estimates show that the highest cases of Cervical Dysplasia in the 7MM were in the United States, followed by the France, Germany, Italy, the United Kingdom, Japan, and Spain in 2020.
 In the year 2020, the total diagnosed incident cases of cervical dysplasia by severity were 2,373,043 (CIN1) and 519,644 (CIN2+) cases in the 7MM, which are expected to grow during the study period, i.e., 2018-2030.
 The US accounted for 17,894, 91,458, and 85,493 cases for age groups specific cases of CIN 2+ for 18-24 years, 25-34 years, and ≥35 years age group, respectively, in the year 2020, which will probably rise for the age groups 18-24 years, and ≥35 years, respectively, however for the age groups 25-34 years the cases will probably decrease during the study period i.e., 2018-2030.
 Japan accounted for 2,220, 10,173, and 55,642 treated cases of cervical dysplasia for age groups 18-24 years, 25-34 years, and ≥35 years, respectively, in the year 2020.
Scope of the Report
• The Cervical Dysplasia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Cervical Dysplasia Report and Model provide an overview of the risk factors and global trends of Cervical Dysplasia in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Cervical Dysplasia in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Cervical Dysplasia.
• The report provides the segmentation of the Cervical Dysplasia epidemiology by total diagnosed incident cases in the 7MM.
• The report provides the segmentation of the Cervical Dysplasia epidemiology by total diagnosed incident cases by severity (without year on year impact of vaccination) in the 7MM.
• The report provides the segmentation of the Cervical Dysplasia epidemiology by total age group-specific cases (CIN 2+, with impact of HPV vaccination) in the 7MM.
• The report provides the segmentation of the Cervical Dysplasia epidemiology by total treated cases in the 7MM.
Report Highlights
• 10-Year Forecast of Cervical Dysplasia epidemiology
• 7MM Coverage
• Total Diagnosed Incident Cases of Cervical Dysplasia
• Total Diagnosed Incident Cases by Severity (without year on year impact of vaccination) of Cervical Dysplasia
• Total Age group-Specific Cases (CIN 2+, with impact of HPV vaccination) of Cervical Dysplasia
• Total Treated Cases of Cervical Dysplasia
KOL-Views
We interview KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population of Cervical Dysplasia?
• What are the key findings of the Cervical Dysplasia epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of patients of Cervical Dysplasia across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Cervical Dysplasia?
Reasons to buy
The Cervical Dysplasia Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Cervical Dysplasia market
• Quantify patient populations in the global Cervical Dysplasia market to improve product design, pricing, and launch plans
• Understand the magnitude of Cervical Dysplasia population by its age group-specificity
• The Cervical Dysplasia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Cervical Dysplasia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030
• In the year 2020, the total diagnosed incident cases of cervical dysplasia were 2,892,687 cases in the 7MM, which are expected to grow during the study period, i.e.,2018-2030.
• In the year 2020, the total diagnosed incident cases of cervical dysplasia by severity were 2,373,043 (CIN1) and 519,644 (CIN2) cases in the 7MM, which are expected to grow during the study period, i.e., 2018-2030.
• In the year 2020, the total age group-specific cases of CIN 2+ were 28,880, 189,792, and 292,711 cases for age groups 18-24 years, 25-34 years, and ≥35 years, respectively, in the 7MM, which might increase for age groups 18-24 years, and ≥35 years, respectively. However in the age group 25-34 years the cases will probably decrease during the study period i.e., 2018-2030.
• In the year 2020, the total treated cases of cervical dysplasia were 17,328, 132,855, and 248,804 cases for age groups 18-24 years, 25-34 years, and ≥35 years, respectively, in the 7MM, which might increase for the age groups 18-24 years, and ≥35 years, respectively, by 2030. However in the age group 25-34 years the cases will probably decrease.